Adage Capital Partners Gp, L.L.C. Avidity Biosciences, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,145,881 shares of RNA stock, worth $66.5 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
2,145,881
Previous 2,751,944
22.02%
Holding current value
$66.5 Million
Previous $80 Million
20.84%
% of portfolio
0.12%
Previous 0.15%
Shares
10 transactions
Others Institutions Holding RNA
# of Institutions
244Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$354 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$351 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$300 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$286 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$271 Million4.23% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.61B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...